Syndax Pharmaceuticals
$23.72
0
+$0+0% Wednesday 06:41
Statistics
Day High
24.7
Day Low
23.72
52W High
-
52W Low
-
Volume
1,239
Avg. Volume
-
Mkt Cap
2.09B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
11MayExpected
Expected EPS
-0.622985
Actual EPS
N/A
Financials
-165.6%Profit Margin
Unprofitable344.7MRevenue
-570.84MNet Income
Analyst Ratings
$43.11Average Price Target
The highest estimate is 57.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow SNDX.BOATS. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap298.84B
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Astrazeneca
AZN
Mkt Cap315.47B
Pfizer
PFE
Mkt Cap161.09B
Gilead Sciences
GILD
Mkt Cap173.41B
AMGEN
AMGN
Mkt Cap187.56B
Novartis
NVS
Mkt Cap297.32B
Roche
RHHBY
Mkt Cap321.08B
Incyte
INCY
Mkt Cap19.09B
Exelixis
EXEL
Mkt Cap11.76B
About
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Show more...
CEO
ISIN
US87164F1057
Listings
0 Comments
Share your thoughts
FAQ
What is Syndax Pharmaceuticals stock price today?▼
The current price of SNDX.BOATS is $23.72 USD — it has increased by +0% in the past 24 hours. Watch Syndax Pharmaceuticals stock price performance more closely on the chart.
What is Syndax Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Syndax Pharmaceuticals stocks are traded under the ticker SNDX.BOATS.
What is Syndax Pharmaceuticals market cap?▼
Today Syndax Pharmaceuticals has the market capitalization of 2.09B
When is the next Syndax Pharmaceuticals earnings date?▼
Syndax Pharmaceuticals is going to release the next earnings report on May 11, 2026.
What were Syndax Pharmaceuticals earnings last quarter?▼
SNDX.BOATS earnings for the last quarter are -0.78 USD per share, whereas the estimation was -0.58 USD resulting in a -33.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Syndax Pharmaceuticals revenue for the last year?▼
Syndax Pharmaceuticals revenue for the last year amounts to 344.7M USD.
What is Syndax Pharmaceuticals net income for the last year?▼
SNDX.BOATS net income for the last year is -570.84M USD.
When did Syndax Pharmaceuticals complete a stock split?▼
Syndax Pharmaceuticals has not had any recent stock splits.